Abstract

Microfluidics in Preclinical Research

Jing Chen, CEO, HiComp Microtech

Microfluidics revolutionizes preclinical research with precise control, reduced sample use, and high-throughput screening. It enhances drug development, organ-on-a-chip models, cancer research, and diagnostics with improved sensitivity and real-time analysis. Technological advancements and successful applications showcase its promising future despite technical and regulatory challenges.